GLP-1 drugs can lower employer health care costs over the long term but almost always increase them in the short term. Right now, these medications significantly raise pharmacy spending—often thousands of dollars per employee per year—driving higher premiums and plan costs. However, evidence suggests that after one to two years, employees using GLP-1s may experience slower medical cost growth due to fewer obesity-related complications, such as diabetes progression and cardiovascular events. Whether employers ultimately save money depends on drug pricing, coverage restrictions, employee adherence, and how long employers are willing to wait for downstream medical savings to offset the upfront drug costs.
The Sticker Shock: Why GLP-1s Are Driving Up Costs Right Now
- They’re incredibly expensive.
A single employee on a GLP-1 drug like Wegovy or Zepbound can easily cost a company over $10,000 a year. It’s no surprise that these medications have quickly become one of the biggest drivers of pharmacy spending for employers. - Premiums are on the rise.
This spending spree is forcing costs up across the board. Research from Blue Cross and Blue Shield suggests that covering these drugs could increase health insurance premiums by 6-14%, depending on plan design and treatment adherence. - Pharmacy budgets are exploding.
Companies are already feeling the pinch. One analysis found that employers spent nearly $900 million on the top three GLP-1s in 2023, and that number is rising rapidly.
The bottom line: For the next year or two, covering these drugs almost certainly means you’ll be paying more.
The Payoff: How GLP-1s Could Save Money in the Long Run
- Long-term data show they can slow medical spending.
A major study of nearly 140,000 workers found an interesting finding. While medical costs rose in the first year (due to more doctor visits), by the second year, the growth in medical spending for people on GLP-1s was about half that of their peers. This was mainly because they had fewer heart attacks, strokes, and other serious health events tied to obesity. - Better health means fewer big bills down the road.
These drugs do more than support weight loss; they can prevent or improve chronic conditions that are highly costly for employers, both in medical claims and lost productivity.
The bottom line: Over several years, the health improvements from GLP-1s can start to bend the cost curve, but that doesn’t happen overnight, and it won’t magically erase the high initial cost of the drugs themselves.
Will Your Company Actually Save Money? It Depends.
Whether these drugs end up being a net positive for your bottom line comes down to a few key things:
- The Price Tag: The single biggest factor. If drug prices come down or rebates improve, the math looks much more favorable.
- Who’s Covered: Are you covering GLP-1s for everyone, or only for employees with specific high-risk conditions? Tighter eligibility can control the initial spending spike.
- How Long People Stick With It: For the health benefits to kick in, employees need to take the medication consistently. This means higher pharmacy costs but also a better shot at long-term medical savings.
- Your Team’s Health Profile: If your workforce has a higher prevalence of obesity, diabetes, or risk factors for heart disease, the potential for positive health outcomes—and cost savings—is much greater.
How Employers Are Handling It
To manage the high price tag without losing the potential benefits, many companies are trying a few things:
- Requiring prior authorization to ensure the medication is medically necessary.
- Setting up different cost-sharing tiers for weight loss versus diabetes treatment.
- Pairing the drugs with lifestyle and weight management programs to get the best results.
- Getting tougher in negotiations with their PBMs to secure better pricing.
Putting It All Together
So, what’s the verdict?
In the short term, there’s no getting around it: GLP-1s are expensive and will drive up your health plan costs. The high price of the drugs and the number of people using them are causing pharmacy spending and premiums to spike.
The long-term picture is more hopeful. By improving employee health and preventing costly events such as heart attacks and diabetes complications, these drugs have the potential to reduce your overall medical spending. Whether you actually “come out ahead” depends on a balancing act—negotiating good prices, setting smart coverage rules, and seeing your employees’ health truly improve over time.

